Clinical trials: Overweight and Obesity
Healthy Participants
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations
The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.
- Trial name
- NCT06996886
- Testing
- AZD5004
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity &Amp; Overweight
UBT251 Injection Phase II Study (Overweight or Obesity)
This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
- Trial name
- NCT07177469
- Where
- China
- Volunteers
- 205 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Overweight and Obesity
To Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals
CitruSlim® can promote healthy weight loss by promoting anabolic state during weight loss programs, prevent the body from storing fat, reduce appetites and maintain healthy cholesterol and blood glucose level during weight loss…
- Trial name
- NCT03973086
- Testing
- Citrus flavonone-O-glycosides- LD, Citrus flavonone-O-glycosides- HD
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Prader-Willi Syndrome
Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin).
- Trial name
- CARE-PWS (NCT03649477)
- Testing
- 3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 130 people
- Sponsor
- Levo Therapeutics, Inc.
Obesity
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
- Trial name
- ATTAIN-J (NCT05931380)
- Testing
- Orforglipron
- Where
- 16 sites in Japan
- Volunteers
- 238 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE）
This study is testing how overweight and obesity affect cardiovascular disease (CVD) prevalence, risk factors, and mortality among Chinese adults using nationally representative CCDRFS (China Chronic Disease and Risk Factor…
- Trial name
- COPE (NCT07358052)
- Testing
- No treatment given
- Where
- 2 sites in China
- Volunteers
- 551,931 people
- Sponsor
- Novo Nordisk A/S
Overweight/Obesity
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
The study is being conducted to evaluate the bioequivalence between a single-dose pen and a multi-dose pen of HRS9531 injection solution.
- Trial name
- NCT06792955
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Weight Management in Adult Patients With Obesity or Overweight
Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult…
- Trial name
- NCT07205432
- Testing
- XTL6001
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shanghai Xitaili Biomedicine Technology co., Ltd.
Obese
Safety and Pharmacokinetics of HU6
Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1…
- Trial name
- NCT05433506
- Testing
- HU6 Tablet, HU6 Capsule
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Obesity
Endostapler Gastric Bypass Study
The goal of this prospective, post-market study is to evaluate safety and efficacy of the AEON™ Endostapler when used in laparoscopic Roux-en-Y gastric bypass surgery.
- Trial name
- NCT04712526
- Testing
- AEON Endostapler
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Lexington Medical Inc.
Healthy Overweight Obese
The Effect of Gelesis100 on the Pharmacokinetics of Metformin
The purpose of this study is to determine the effect of Gelesis100 on the absorption of metformin both with and without a meal.
- Trial name
- NCT02524821
- Testing
- Gelesis100, Metformin
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gelesis, Inc.
Depression
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
- Trial name
- NCT00624858
- Testing
- naltrexone SR 32 mg/ bupropion SR 360 mg daily
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects…
- Trial name
- NCT05064735
- Testing
- semaglutide 2.4 mg
- Where
- 122 sites in United States, Canada and 9 more
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Gastrointestinal, Overweight , Obesity
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals
Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies.
- Trial name
- NCT07336615
- Testing
- CLB101™️
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- ClostraBio Inc.
Overweight/Obesity
Bioequivalence Study of BGM0504 Injection
This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference…
- Trial name
- NCT07382908
- Testing
- BGM0504 Injection multi-dose pen, BGM0504 Injection single-dose pen
- Where
- China
- Volunteers
- 144 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity Hypoventilation Syndrome
AVAPS-AE Efficacy Study
The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV)…
- Trial name
- NCT01368614
- Testing
- AVAPS-AE Mode of Therapy, Respironics OnmiLab BiPAP S mode, Respironics OmniLab Advanced CPAP mode
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Philips Respironics
Overweight, Obesity
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends.
- Trial name
- SELECT-LIFE (NCT04972721)
- Testing
- No treatment given
- Where
- 38 sites in United States, Algeria and 22 more
- Volunteers
- 3,439 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Obesity
Multi-Center Feasibility Study of Trans-oral Endoscopic Restrictive Implant System (TERIS) for Treatment of Obesity
The Barosense Trans-oral Endoscopic Restrictive Implant System (TERIS) is an investigational system being evaluated for safety The system uses endoscopic guidance to trans-orally implant a restrictive reservoir for food entering…
- Trial name
- NCT00707720
- Testing
- TERIS procedure
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- BaroSense Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.